Fig. 3: Effects of anti-amyloidogenic compounds on the structure of α-Synuclein upon in vitro aggregation. | npj Parkinson's Disease

Fig. 3: Effects of anti-amyloidogenic compounds on the structure of α-Synuclein upon in vitro aggregation.

From: An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ

Fig. 3

Structures of ACI compound 1 (A; N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-6-methoxy-9-methyl-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indol-2-amine) and ACI compound 2 (B; (6 R)-N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N6,9-dimethyl-5,6,7,8-tetrahydropyrido[2,3-b]indole-2,6-diamine). C ThT signal over a 17 h α-Synuclein aggregation assay in the indicated conditions (molar ratio compound/α-Synuclein of 5.7). D ThT fluorescence signal intensity after 17 h of incubation (TEnd). E Half time (T½) of aggregation extracted from ThT fluorescence curve profile. Inf, infinite. F–L Structural fingerprints comparing the initial and final α-Synuclein structures under the indicated conditions: DMSO control condition (F), Fasudil (G), compound 1 (H), Doxycycline (I), compound 2 (J), Baicalein (K) and EGCG (L). The scale indicates the score per amino acid. The significance threshold of −log10(0.05) × log2(2) is shown in white, with red indicating higher scores. The more intense the red color, the higher the score. Not significant in gray. Not detected in yellow. N-term N-terminus, NAC non-amyloid β component (aa 61–95), C-term C-terminus.

Back to article page